Lupin Hits 91/100 in S&P ESG, Ranks 1st Globally in Pharma

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Lupin Hits 91/100 in S&P ESG, Ranks 1st Globally in Pharma
Overview

Lupin Limited has achieved a remarkable score of 91 out of 100 in the S&P Global Corporate Sustainability Assessment 2025. This places the company at the forefront, ranking first globally in the pharmaceutical sector and first across all sectors in India. This is Lupin's third consecutive year of inclusion in the prestigious Sustainability Yearbook 2026.

Lupin Soars to Global Pharma ESG Summit with 91/100 S&P Score

Lupin Limited has achieved an outstanding S&P Global Corporate Sustainability Assessment score of 91 out of 100, marking it as the top-ranked global pharma company and number one across all sectors in India.
This recognition places Lupin among an elite group of companies worldwide to surpass the 90-point threshold in the S&P Global ESG assessment.

What just happened (today’s filing)

Global pharmaceutical major Lupin Limited announced its remarkable achievement in the S&P Global Corporate Sustainability Assessment 2025, scoring a near-perfect 91 out of 100. [cite:GROUNDED_2,3,4]

The company secured the top position globally within the pharmaceutical sector and also ranked first across all industries in India. [cite:GROUNDED_2,3,4]

This marks Lupin's third consecutive year of inclusion in the prestigious S&P Global Sustainability Yearbook 2026, underscoring its sustained commitment to responsible business practices. [cite:GROUNDED_2,3,4]

Why this matters

An exceptionally high ESG score like Lupin's signifies robust environmental stewardship, strong social impact, and sound corporate governance. [cite:GROUNDED_2,3,4]

For investors, this recognition enhances the company's attractiveness, particularly for those prioritizing Environmental, Social, and Governance (ESG) factors in their investment decisions. [cite:GROUNDED_3,5,8]

It reinforces Lupin's strategic focus on integrating sustainability into its core business operations, potentially leading to better risk management, enhanced brand reputation, and improved stakeholder trust. [cite:GROUNDED_2,17,19]

The backstory (grounded)

Lupin's ESG journey shows a rapid upward trajectory. Its S&P Global ESG score has dramatically improved from 17 in 2021 to 76 in 2024, and now 91 in 2025, one of the fastest climbs in the pharmaceutical industry. [cite:GROUNDED_17,19,30]

The company has also secured the highest 'A' leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. [cite:GROUNDED_24]

Lupin has a history of being recognized in the S&P Global Sustainability Yearbook, with inclusions in 2025 and 2024, highlighting a consistent focus on sustainability. [cite:GROUNDED_27,34]

What changes now

  • Enhanced corporate reputation and brand value globally.
  • Increased attractiveness to ESG-focused institutional investors and funds.
  • Strengthened stakeholder relations with employees, communities, and customers.
  • Potential for better access to capital and lower cost of capital due to improved ESG standing.
  • Reinforces strategic direction and commitment to sustainable growth initiatives.

Risks to watch

Despite its ESG leadership, Lupin has faced regulatory challenges. It was penalized ₹2.28 crore by the West Bengal GST Appeal Authority for wrongful Input Tax Credit (ITC) utilization for FY 2017-2018 and plans to appeal the order. [cite:GROUNDED_35,36]

Globally, Lupin and its subsidiaries have also incurred significant penalties for practices including price-fixing and anti-competitive conduct, False Claims Act violations, and controlled substances violations, amounting to hundreds of millions of dollars over recent years. [cite:GROUNDED_37]

Peer comparison

Lupin's score of 91/100 and first-place global pharma ranking significantly outpaces its peers. [cite:GROUNDED_2,11,23,28,31]

Dr. Reddy's Laboratories achieved a 78/100 S&P Global ESG score in 2023 and inclusion in the Dow Jones Sustainability World Index. [cite:GROUNDED_11,23]

Cipla received ESG ratings around 66-68 from other providers in late 2025. [cite:GROUNDED_3,4,5]

Sun Pharma was included in the S&P Global Sustainability Yearbook 2024 and 2025, recognized among the top 5% globally. [cite:GROUNDED_28,34]

Context metrics (time-bound)

  • S&P Global ESG Score for Lupin Limited stands at 91 out of 100 for 2025.

What to track next

  • Continued progress and specific targets for environmental footprint reduction (e.g., net-zero emissions, water positivity).
  • Employee well-being initiatives, diversity and inclusion metrics, and community health programs.
  • Board-level oversight and transparency in addressing ESG risks and opportunities.
  • How this high ESG standing translates into tangible business benefits, such as cost savings or enhanced investor relations.
  • Future ESG ratings and recognitions from other global bodies.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.